Literature DB >> 21801515

Predictors of incident atrial fibrillation and influence of medications: a retrospective case-control study.

James A Hodgkinson1, Clare J Taylor, F D Richard Hobbs.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is a common condition, associated with raised mortality and risk of major morbidity, and is predicted to increase due to an aging population. AIM: To update earlier research of AF predictors using UK data. DESIGN AND
SETTING: Case-control analysis of adults aged 18 years and older with a diagnosis of AF in practices registered with the General Practice Research Database (GPRD) in the UK.
METHOD: Using the GPRD, a case.control analysis was performed using logistic regression to compare 55,412 incident AF cases to 216,400 controls, for medical history and prior use of drugs. The association between time since start of diagnosis or drug use and AF risk was summarised using Spline regression.
RESULTS: The following were confirmed as risk factors for AF: heart failure (risk ratio [RR] 2.91 [95% CI = 2.59 to 3.27]); ischaemic heart disease (IHD) (RR 2.00 [95% CI = 1.78 to 2.24]); hypertension (RR 2.60 [95% CI = 2.32 to 2.92]); hyperthyroidism (RR 1.56 [95% CI = 1.39 to 1.75]); being a heavy drinker (RR 1.43 [95% CI = 1.27 to 1.60]); cerebrovascular accident (RR 1.48 [95% CI = 1.32 to 1.66]); and obesity (body mass index ≥30 kg/m(2) RR 1.29 [95% CI = 1.15 to 1.45]). Current use of oral glucocorticoids (RR 1.62 [95% CI = 1.44 to 1.82]) and of beta-2 agonists (RR 1.30 [95% CI = 1.16 to 1.46]) were identified as significant risk factors, and statins (RR 0.82 [95% CI = 0.73 to 0.92]) as a significant protective factor. No effect was found for current use of bisphosphonates (RR 0.95 [95% CI = 0.85 to 1.07]), renin.angiotensin.aldosterone system (RAAS) agents (RR 1.04 [95% CI = 0.93 to 1.17]), or xanthine derivatives (RR 1.09 [95% CI = 0.97 to 1.22]). Spline regression analysis found the effect of heart failure, IHD, use of oral glucocorticoids, and use of statins on the likelihood of developing AF was sustained over a number of years.
CONCLUSION: These findings update the risk factors that are associated with AF, and confirm the protective properties of statins and the risks of beta-2 agonists in developing AF, but not the supposed protective qualities of glucocorticoids and RAAS agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21801515      PMCID: PMC3103699          DOI: 10.3399/bjgp11X578034

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  58 in total

1.  Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial.

Authors:  David A Fitzmaurice; F D Richard Hobbs; Sue Jowett; Jonathon Mant; Ellen T Murray; Roger Holder; J P Raftery; S Bryan; Michael Davies; Gregory Y H Lip; T F Allan
Journal:  BMJ       Date:  2007-08-02

2.  Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database.

Authors:  A Majeed; K Moser; K Carroll
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

3.  Atrial fibrillation and antithrombotic therapy in a 75-year-old population.

Authors:  Arnljot Tveit; Michael Abdelnoor; Steve Enger; Pal Smith
Journal:  Cardiology       Date:  2007-09-17       Impact factor: 1.869

4.  Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials.

Authors:  Laurent Fauchier; Bertrand Pierre; Axel de Labriolle; Caroline Grimard; Noura Zannad; Dominique Babuty
Journal:  J Am Coll Cardiol       Date:  2008-02-26       Impact factor: 24.094

5.  Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension.

Authors:  Frank de Vries; Sander Pouwels; Madelon Bracke; Jan-Willem Lammers; Olaf Klungel; Hubert Leufkens; Tjeerd van Staa
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 6.  Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies.

Authors:  Tong Liu; Lijian Li; Panagiotis Korantzopoulos; Enzhao Liu; Guangping Li
Journal:  Int J Cardiol       Date:  2007-11-26       Impact factor: 4.164

7.  Use of alendronate and risk of incident atrial fibrillation in women.

Authors:  Susan R Heckbert; Guo Li; Steven R Cummings; Nicholas L Smith; Bruce M Psaty
Journal:  Arch Intern Med       Date:  2008-04-28

8.  Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.

Authors:  John P Hanrahan; Donna R Grogan; Rudolf A Baumgartner; Amy Wilson; Hailong Cheng; Peter J Zimetbaum; Joel Morganroth
Journal:  Medicine (Baltimore)       Date:  2008-11       Impact factor: 1.889

Review 9.  Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis.

Authors:  Mhamad B Jibrini; Janos Molnar; Rohit R Arora
Journal:  Am J Ther       Date:  2008 Jan-Feb       Impact factor: 2.688

10.  Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis.

Authors:  Anthony Grosso; Ian Douglas; Aroon Hingorani; Raymond MacAllister; Liam Smeeth
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

View more
  8 in total

1.  Chocolate Consumption and Risk of Atrial Fibrillation (from the Physicians' Health Study).

Authors:  Owais Khawaja; Andrew B Petrone; Yousuf Kanjwal; John M Gaziano; Luc Djoussé
Journal:  Am J Cardiol       Date:  2015-05-21       Impact factor: 2.778

2.  Consumption of fried foods and risk of atrial fibrillation in the Physicians' Health Study.

Authors:  Owais Khawaja; Howard D Sesso; Jiaying Chen; Hiroshi Yamasaki; Sohail A Hassan; John M Gaziano; Luc Djoussé
Journal:  Eur J Nutr       Date:  2019-03-27       Impact factor: 5.614

3.  Sleep duration and risk of atrial fibrillation (from the Physicians' Health Study).

Authors:  Owais Khawaja; Akmal Sarwar; Christine M Albert; John Michael Gaziano; Luc Djoussé
Journal:  Am J Cardiol       Date:  2012-12-06       Impact factor: 2.778

4.  Acute effect of zoledronic acid on the risk of cardiac dysrhythmias.

Authors:  Cristiana Cipriani; Claudia Castro; Mario Curione; Sara Piemonte; Federica Biamonte; Claudio Savoriti; Jessica Pepe; Federica De Lucia; Carolina Clementelli; Luciano Nieddu; Salvatore Minisola
Journal:  Intern Emerg Med       Date:  2014-09-05       Impact factor: 3.397

5.  Impact of gout on the risk of atrial fibrillation.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Christian Mallen; Weiya Zhang; Michael Doherty
Journal:  Rheumatology (Oxford)       Date:  2015-12-17       Impact factor: 7.580

Review 6.  Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies.

Authors:  Dagfinn Aune; Abhijit Sen; Sabrina Schlesinger; Teresa Norat; Imre Janszky; Pål Romundstad; Serena Tonstad; Elio Riboli; Lars J Vatten
Journal:  Eur J Epidemiol       Date:  2017-02-13       Impact factor: 8.082

7.  Sex Differences in the Impact of Body Mass Index on the Risk of Future Atrial Fibrillation: Insights From the Longitudinal Population-Based Tromsø Study.

Authors:  Jocasta Ball; Maja-Lisa Løchen; Tom Wilsgaard; Henrik Schirmer; Laila A Hopstock; Bente Morseth; Ellisiv B Mathiesen; Inger Njølstad; Sweta Tiwari; Ekaterina Sharashova
Journal:  J Am Heart Assoc       Date:  2018-04-19       Impact factor: 5.501

8.  Potential therapeutic competition in community-living older adults in the U.S.: use of medications that may adversely affect a coexisting condition.

Authors:  Songprod Jonathan Lorgunpai; Marianthe Grammas; David S H Lee; Gail McAvay; Peter Charpentier; Mary E Tinetti
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.